# POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).

> **NCT00700401** · — · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 262 (actual)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** peginterferon alfa-2a [Pegasys]
- **DRUG:** ribavirin [Copegus]

## Key facts

- **NCT ID:** NCT00700401
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 262 (ACTUAL)
- **Last updated:** 2016-06-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00700401

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00700401, "POTENTE Study: A Study of Early Virological Response in Naive Patients With Chronic Hepatitis C, Genotype 2 or 3, Treated With PEGASYS (Peginterferon Alfa-2a (40KD)) Plus Copegus (Ribavirin).". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00700401. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*